| 2020 | 2021 | 2022 | 2023 | 2024 | |
| Phase I-II | 2,422,798.00€ | 3,261,220.00€ | 3,294,597.29€ | 3,855,869.30€ | 4,270,565.22 € |
| Phase III | 3,359,925.00€ | 4,343,587.00€ | 4,388,041.88€ | 5,367,816.79€ | 5,948,831.58 € |
| Phase IV | 144,704.00€ | 289,781.00€ | 292,746.79€ | 151,994.86€ | 403,656.80 € |
| EOM/MD | 350,981.00€ | 350,411.00€ | 353,997.32€ | 378,462.66€ | 565,132.89 € |
| TOTAL | 6,278,408.00€ | 8,244,999.00€ | 8,329,383.28€ | 9,754,143.60€ | 11,188,186.48 € |
New Clinical Studies
169
Clinical trials
54
EOM (Post authorization study)
18
MD (Medical device study)
* New clinical studies (241) include clinical trials, post authorization studies and medical device studies.
Active Clinical Studies
681
Clinical trials
289
EOM (Post authorization study)
58
MD (Medical device study)
221
Clinical Trials on Rare Diseases
194
Clinial Trials on Pediatrics
638
Clinical Trials patient inclusions in 2024
* Active clinical studies (1028) include clinical trials, post authorization studies and medical device studies.
Active Clinical Studies 5-year evolution
Patient inclusions 5-year evolution
Active Clinical Studies by eCORE
Billing evolution of clinical studies
Definitions & methodology
The data are at VHIR level, not at Campus level (not including data from VHIO/Adult Oncology and Hematology Services).
The data includes commercial and academic studies that are registered in the database.
eCORE “Others”: studies of researchers who are not part of any research area of VHIR but belong to a Service of Vall d’Hebron Hospital.
New: studies with signed contract+AEMPS+CEIm.
Active: active+new+closed studies in the year.
